Nuvectra Corporation (NVTR) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. raised its position in Nuvectra Corporation (NASDAQ:NVTR) by 6.2% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 310,794 shares of the company’s stock after acquiring an additional 18,081 shares during the quarter. Vanguard Group Inc. owned approximately 3.01% of Nuvectra worth $4,128,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of NVTR. Gilder Gagnon Howe & Co. LLC lifted its holdings in Nuvectra by 12.5% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 953,431 shares of the company’s stock valued at $12,662,000 after acquiring an additional 105,580 shares during the period. Hodges Capital Management Inc. lifted its holdings in Nuvectra by 18.6% in the second quarter. Hodges Capital Management Inc. now owns 227,807 shares of the company’s stock valued at $3,025,000 after acquiring an additional 35,706 shares during the period. Northern Trust Corp lifted its holdings in Nuvectra by 1.7% in the second quarter. Northern Trust Corp now owns 169,659 shares of the company’s stock valued at $2,253,000 after acquiring an additional 2,811 shares during the period. Wells Fargo & Company MN increased its position in Nuvectra by 1.3% in the second quarter. Wells Fargo & Company MN now owns 114,492 shares of the company’s stock worth $1,520,000 after buying an additional 1,495 shares in the last quarter. Finally, Gamco Investors INC. ET AL increased its position in Nuvectra by 4.2% in the second quarter. Gamco Investors INC. ET AL now owns 35,194 shares of the company’s stock worth $467,000 after buying an additional 1,434 shares in the last quarter. 58.89% of the stock is currently owned by institutional investors.

Shares of Nuvectra Corporation (NASDAQ NVTR) opened at $9.00 on Tuesday. The company has a quick ratio of 2.72, a current ratio of 2.90 and a debt-to-equity ratio of 0.37. Nuvectra Corporation has a 1 year low of $4.90 and a 1 year high of $15.00.

Nuvectra (NASDAQ:NVTR) last released its earnings results on Wednesday, November 1st. The company reported ($1.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.07. Nuvectra had a negative return on equity of 68.63% and a negative net margin of 204.19%. The firm had revenue of $7.60 million during the quarter, compared to analysts’ expectations of $8.08 million. During the same quarter last year, the business posted ($0.92) earnings per share. The firm’s revenue was up 100.0% on a year-over-year basis.

NVTR has been the subject of a number of analyst reports. ValuEngine cut Nuvectra from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Piper Jaffray Companies restated a “hold” rating and issued a $12.00 price target on shares of Nuvectra in a research report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $12.00.

TRADEMARK VIOLATION NOTICE: “Nuvectra Corporation (NVTR) Shares Bought by Vanguard Group Inc.” was first reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.truebluetribune.com/2017/12/12/vanguard-group-inc-has-4-13-million-position-in-nuvectra-corporation-nvtr.html.

About Nuvectra

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.

Institutional Ownership by Quarter for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply